 |
Clinical Trials, Phase II as Topic
Research News and Information
Definition of 'Clinical Trials, Phase II as Topic'Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries. |
Sunday, November 22, 2009
Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
18 Oct 2009 
OBJECTIVE: To describe the characteristics of children enrolled in treatment trials for neurofibromatosis type 1 (NF1)-related plexiform neurofibroma (PN), PN tumor burden, PN-related complications, and treatment outcomes and to highlight the ... Read more...
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
29 Sep 2009 Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been shown to improve overall survival in patients with locally advanced SCCHN ... Read more...
29 Sep 2009 BACKGROUND: Gonadotropin-releasing hormone (GnRH) analogues are used routinely to prevent a premature luteinizing hormone (LH) surge in women undergoing assisted reproductive technology (ART) treatments. In contrast to GnRH agonists, antagonists ... Read more...
Latest indexed articles for 'Clinical Trials, Phase II as Topic'
These are the very latest articles for this heading:
- Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. 18 Oct 2009
- Underestimation of the effect of bleeding in clinical trials.
Oct 2009 - Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. 29 Sep 2009
- GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology. 29 Sep 2009
- Helical tomotherapy significantly reduces dose to normal tissues when compared to 3D-CRT for locally advanced rectal cancer. 29 Sep 2009
- Cyberknife and prostate cancer. In regard to King et al. (Int J Radiat Oncol Biol Phys 2009;73:1043-1048). 29 Sep 2009
- Progress in primary CNS lymphoma. 16 Sep 2009
- Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. 13 Sep 2009
- Novel evidence-based systemic lupus erythematosus responder index. 13 Sep 2009
- Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. 13 Sep 2009
- Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. 13 Sep 2009
- Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. 6 Sep 2009
- PARP inhibitors: will the new class of drugs match the hype? 6 Sep 2009
- Lymphoma vaccine trial: one step forward in long trek. 6 Sep 2009
- Activity Increase Despite Arthritis (AIDA): design of a Phase II randomised controlled trial evaluating an active management booklet for hip and knee osteoarthritis [ISRCTN24554946]. 2 Sep 2009
- Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. 30 Aug 2009
- Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. 30 Aug 2009
- The development of the RTS,S malaria vaccine candidate: challenges and lessons. 30 Aug 2009
- Otamixaban in acute coronary syndromes. 26 Aug 2009
- Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? 22 Aug 2009
See a longer list of these articles.
Technical information about 'Clinical Trials, Phase II as Topic'
Definition: Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
Descriptor UI: D017322
Alternative terms: Clinical Trials, Phase II as Topic; Drug Evaluation, FDA Phase II as Topic; Drug Evaluation, FDA Phase 2 as Topic; Evaluation Studies, FDA Phase II as Topic; Evaluation Studies, FDA Phase 2 as Topic;
Allowable Qualifiers: adverse effects; classification; economics; history; instrumentation; methods; mortality; nursing; psychology; standards; trends; utilization; veterinary; statistics & numerical data; contraindications; ethics; legislation & jurisprudence;
Tree Number: E05.318.760.535.210; E05.337.250.210; N05.715.360.775.235.210; N06.850.520.450.535.210;
History Note: 2008(1993)
Technical Notes: for general design, methodology, economics, etc. of phase II clinical trials; a different heading CLINICAL TRIAL, PHASE II is used for reports of a specific phase II clinical trial